NASDAQ$TNGX

Tango Therapeutics Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Headline financials

Total Revenue

$5.72M

No prior period
EPS (adj)

-$0.25

No prior period
Capital Expenditures

$696K

No prior period
Free Cash Flow

-$17.6M

No prior period
Net Income

-$22M

No prior period
Operating Income

-$22M

No prior period
Gross Profit

$5.72M

No prior period
Cash & Equivalents

$143M

No prior period
Total Assets

$500M

No prior period
Stock-Based Comp

$2.26M

No prior period

Revenue & EPS history

Tango Therapeutics · Revenue · Quarterly

$5.72M

Q4 2021
Beat estimate in 6 of 14 quarters(43%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.6%

Avg return

Earnings day

+6.7%

Avg return

5 days after

+25.5%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+36.4%

Q4 2025

Best reaction

-45.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.6%-12.1%
Q4 2025+36.4%+33.6%+75.1%
Q3 2025+0.2%-1.7%+23.6%
Q1 2025+17.1%+31.6%+315.8%
Q4 2024-6.5%-21.0%-36.9%
Q3 2024-45.4%-34.7%-34.7%
Q2 2024-1.8%-5.7%+20.9%
Q1 2024-0.8%-6.9%-12.1%
Q4 2023-9.7%-14.4%-17.4%
Q3 2023+3.8%-12.1%+6.6%
Q2 2023+1.2%+120.9%+113.5%
Q1 2023+6.4%+4.4%-0.3%
Q4 2022-9.4%-5.3%-21.6%
Q3 2022-5.3%+6.7%-1.3%
Q2 2022+22.4%+32.8%-8.1%
Q1 2022-7.6%+1.2%-3.8%
Q4 2021+0.3%+6.8%+1.3%
Q3 2021+0.4%+5.2%-10.7%
Q2 2021+1.1%-2.2%+49.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro